Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis — Yuri Falzone (2022) | RDL Network
Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis
Article 2022 en
Authors
YF
Yuri Falzone
TD
Teuta Domi
AM
Alessandra Mandelli
Abstract
1 min read
NfL is a useful biomarker for the diagnosis of ALS and the strongest predictor of survival. UCHL1 is an independent prognostic factor helpful in stratifying survival in patients with low NfL levels, likely to have slowly progressive disease. GFAP reflects extramotor involvement, namely cognitive impairment or frontotemporal dementia.
Benjamin Gille, Maxim De Schaepdryver, Janne Goossens, Lieselot Dedeene, Joke De Vocht, Emanuela Oldoni, An Goris, Ludo Van Den Bosch, Bart Depreitere, Kristl G. Claeys, Jos Tournoy, Philip Van Damme, Koen Poesen
Discussion(0)
No comments yet. Be the first to comment.